Cellnovo Group provides an update on its partnership with Diabeloop SA for the development of an artificial pancreas solution. Following the positive results of an initial clinical study carried out in 2016, Diabeloop and CERIDT, a non-profit research and care organisation focused on diabetes, launched a clinical study in April 2017 aimed at obtaining the CE mark registration for an artificial pancreas system. The study was undertaken by Diabeloop by combining their proprietary algorithm with Cellnovo’s insulin pump. As recently announced, the first arm of this study is now completed and the second arm is scheduled to start by the end of 2017. The first arm of this study, for which full data will not be published until the completion of the study, reports very positive feedback from patients and investigator sites. It also allowed the identification of modifications required to adapt the Cellnovo pump to specific constraints linked to continuous regulation of the delivered insulin dose, which results in pump operating conditions that differ from standard operations. In collaboration with Diabeloop, Cellnovo’s teams have developed a software solution to ensure complete compatibility of the Cellnovo pump with the Diabeloop algorithm, thus allowing the system to function optimally. However, the necessary modifications are subject to regulatory procedures, which have resulted in delays that prohibit the optimised Cellnovo pump from being used in the second arm of the clinical study. In parallel with this clinical study, Cellnovo and Diabeloop will continue their partnership in order to be able to offer an artificial pancreas solution that is 100% French.